SlideShare a Scribd company logo
Design of
Dosage Regimen
Dr. Ramesh Bhandari
Assistant Professor
Department of Pharmacy Practice
KLE College of Pharmacy, Belagavi
Difference between dosage
form and dosage regimen
Dosage form: the way in which a therapeutic agent
in taken or administered (tablet, capsule, spray).
Dosage regimen: the schedule of doses per unit of
time ( no. of doses and interval).
Introduction
• Dosage regimen design is the selection of drug
dosage, route, and frequency of administration in an
informed manner to achieve therapeutic objectives.
• At the same time, the variability among patients in
pharmacodynamic response demands individualized
dosing to assure maximum efficacy.
• Planning of drug therapy is necessary because the
administration of drugs usually involves risk of
untoward effects.
Several Methods Used to Design a Dosage Regimen
1) Individualized Dosage Regimen
2) Dosage Regimens based on Population averages
3) Dosage Regimens based on Partial Pharmacokinetic
parameters
4) Empirical Dosage Regimen
5) Nomogram and Tabulation in Dosage Regimen
1) Individualized Dosage Regimens
Most accurate approach
 Dose calculated based on the pharmacokinetics of the drug
in the individual patient derived from measurement of serum
/ plasma drug levels
Not feasible for calculation of the initial dose, however, once
the patient has been medicated, readjustment of the dose
may be done.
Most dosing program record the patient’s age and weight and
calculate the individual dose based on creatinine clearance
and lean body weight.
2) Dosage regimen based on population
Averages
The method most often used to calculate a dosage
regimen is based on average pharmacokinetic
parameters obtained from clinical studies published in
the drug literature.
There are 2 approaches followed:
a) Fixed model
b)Adaptive model
a) Fixed Model
• Assumes that population average pharmacokinetic parameters
may be used directly to calculate a dosage regimen for the
patient, without any alteration.
• The practitioner may use the usual dosage suggested by the
literature and then make a small adjustment of the dosage
based on the patient’s weight and / or age
• Usually, pharmacokinetic parameters such as Ka, F, Vd, k are
assumed remain constant and most often drug is assumed to
follow one compartment open model
• When a multiple dose regimen is designed, multiple dosage
equations based on the principle of superposition are used to
evaluate the dose.
b) Adaptive Model
• Attempts to adapt or modify dosage regimen according to the
need of the patient.
• Uses patient variable such as weight, age, sex, body surface
area, and known patient’s pathophysiology such as, renal
disease, as well as known population average pharmacokinetic
parameters of the drug.
• This model generally assumes that pharmacokinetic parameters
such as drug clearance do not change from one dose to the
next.
• However, some adaptive models allow for continuously adaptive
change with time in order to simulate more closely the changing
process of drug disposition in the patient, especially during a
disease state.
3) Dosage regimen based on partial PK
Parameter
• For many drugs, the entire pharmacokinetic profile for the drug is
unknown or unavailable.
• Therefore, the pharmacokineticist needs to make some assumptions in
order to calculate the dosage regimen.
• These assumptions will depend on the safety, efficacy, and therapeutic
range of the drug.
• The use of population pharmacokinetics uses average patient
population characteristics and only a few serum / plasma
concentration from the patient
• Population pharmacokinetic approaches to therapeutic drug monitoring
have increased with the increased availability of computerized data
bases and development of statistical tools for the analysis of
observational data.
4) Empirical Dosage Regimen
• In many cases, physician selects a dosage
regimen of the patient without using any
pharmacokinetic variables.
• The physician makes the decision based on
empirical clinical data, personal experience and
clinical observations.
5) Nomograms andTabulation in Designing
Dosage Regimen
• For ease of calculation of dosage regimens, many
clinicians rely on nomograms to calculate the proper
dosage regimen for their patients.
• The use of nomogram may give a quick dosage regimen
adjustment for patients with characteristics requiring
adjustments such as age, body weight, and physiologic
state.
• In general, nomogram of a drug is based on population
pharmacokinetic data collected and analyzed using a
specific pharmacokinetic model.
Nomograms andTabulation in Designing
Dosage Regimen
• A nomogram typically has three scales: two scales represent
known values and one scale is the scale where the result is
read off.
• The known scales are placed on the outside; i.e. the result
scale is in the center.
• Each known value of the calculation is marked on the outer
scales and a line is drawn between each mark.
• Where the line and the inside scale intersects is the result.
• Examples include: height – BMI – weight,
total clearance – maintenance dose – lean body weight, etc.
Nomograms andTabulation in Designing
Dosage Regimen
• In order to keep the dosage regimen calculation simple,
complicated equations are often solved and their results
displayed diagrammatically on special scaled axes to produce
a simple dose recommendation based on patient information.
• Some nomograms make use of certain physiologic parameters,
such as serum creatinine concentration, to help modify the
dosage regimen according to renal function.
• For many marketed drugs, the manufacturer provides tabulated
general guidelines for use in establishing a dosage regimen for
patients, including loading and maintenance doses.
Examples of drugs for which nomograms are being used
for designing dosage regimen:
• Theophylline
• Aminoglycosides:Tobramycin sulfate
• Warfarin
• Digoxin etc.
CONVERSION FROM
INTRAVENOUS INFUSIONTO ORAL
DOSING
Importance of IV to PO Conversion
oral formulations are easier to administer, safe, and
achieve desired therapeutic concentrations, thus making
the PO route an ideal choice.
More Comfortable
Cost Effective: reduces hidden expenses
IV therapy restrict the movement and make more
prone to IV related adverse effects.
Furthermore, IV route make portal for bacteria and
fungal infections.
Types of IV to PO therapy
Conversion
1) Sequential Therapy
2) Switch Therapy
3) Step-down Therapy
1) SequentialTherapy
It refers to the act of replacing a parenteral version of a
medication with its oral counterpart.
There are many classes of medications that have oral
dosage forms that are therapeutically equivalent to the
parenteral form of the same medication.
E.g. conversion of famotidine 20 mg IV to famotidine
20 mg PO.
2) SwitchTherapy
Used to describe a conversion from an IV medication to
the PO equivalent that may be within the same class and
have the same level of potency, but is a different
compound.
An example is the conversion of IV pantoprazole to
rapidly dissolving lansoprazole tablets omeprazole
capsules.
3) Step-downTherapy
It refers to converting from an injectable medication to
an oral agent in another class or to a different medication
within the same class where the frequency, dose, and the
spectrum of activity (in the case of antibiotics) may not
be exactly the same.
Converting from ampicillin 3 g IV q 6 hr to amoxicillin
875 mg PO q 12 hr is an example of step-down therapy.
SELECTION OF PATIENT FOR IVTO
POTHERAPY CONVERSION
I. Intact and functioning of GI tract
II. Improving patient condition
III.Doesn't meet exclusion criteria
IV.Others
Pharmacokinetic Consideration
• For oral medications, bioavailability may be less due to
the variability in the rate and extent of dissolution of
the oral form and the total amount that is absorbed into
the systemic circulation.
• When intravenous infusion is stopped, the serum drug
concentration decreases according to first-order
elimination kinetics.
• For most oral drug products, the time to reach steady
state depends on the first-order elimination rate
constant for the drug.
• Therefore, if the patient starts the dosage regimen with
the oral drug product at the same time as the intravenous
infusion is stopped, then the exponential decline of
serum levels from the intravenous infusion should be
matched by the exponential increase in serum drug
levels from the oral drug product.
• Following two methods may be used to calculate an
appropriate oral dosage regimen for a patient whose
condition has been stabilized by an intravenous drug
infusion.
• Both methods assume that the patient’s plasma drug
concentration is at steady state.
METHOD I
C∞
av = SFD0 / k Vd τ
D0 / τ = C∞
av . k Vd / SF
Where, S is the salt form of the drug and D0 / τ is the dosing
rate
METHOD II
• This method assumes that the rate of intravenous
infusion (mg/hr) is the same desired rate of oral
dosage.
EXAMPLE
• An adult male asthmatic patient (age 55, 78 kg) has been
maintained on an IV infusion of aminophylline at a rate
of 34 mg/hr. The steady state theophylline drug
concentration was 12 µg/mL and total body clearance
was calculated as 3.0 L/hr. Calculate an appropriate oral
dosage regimen of theophylline for this patient.
(Aminophylline is a soluble salt of theophylline and
contains 85% theophylline (S = 0.85). Theophylline is
100% bioavailable (F = 1) after an oral dose.)
Solution by Method - I
We know, D0 / τ = C∞
av . k Vd / SF
But, total body clearance (ClT) = kVd
Therefore,
D0 / τ = C∞
av ClT/ SF
• The dose rate (34 mg/hr) was calculated on the basis of aminophylline dosing.
• The patient however will be given theophylline orally, to convert to oral
theophylline S and F should be considered
Oral theophylline dose rate = SFD0 / τ = (0.85) (1) (34) / 1 = 28.9 mg / hr
• Therefore the total daily dose is 28.9 mg/hr x 24 hr or 693.6 mg/day
• Possible theophylline schedules might be 700 mg/day.
• The dose of 350 mg every 12 hours could be given in sustained-release form to
avoid any excessive high drug concentration in the body.
Solution by Method - II
Rate of IV infusion is 34 mg/hr and so the daily
dose is 34 mg/hr x 24 = 816 mg/day.
The equivalent dose in terms of theophylline is
816 x 0.85 = 693.6 mg.
Thus the patient should receive approximately
700 mg of theophylline per day or 350 mg every
12 hours.
Design of Dosage form

More Related Content

What's hot

Nomograms and tabulations in design of dosage regimens
Nomograms and tabulations in design of dosage regimens Nomograms and tabulations in design of dosage regimens
Nomograms and tabulations in design of dosage regimens
pavithra vinayak
 
6. population pharmacokinetics
6. population pharmacokinetics6. population pharmacokinetics
6. population pharmacokinetics
PARUL UNIVERSITY
 
Drug dosing in elderly, infant and obese patient slide share
Drug dosing in elderly, infant and obese patient slide shareDrug dosing in elderly, infant and obese patient slide share
Drug dosing in elderly, infant and obese patient slide share
javvadhasan
 
Dose adjustment in Renal failure
Dose adjustment in Renal failure Dose adjustment in Renal failure
Dose adjustment in Renal failure
Mallinath Paramgond
 
Introduction to Bayesian theory
Introduction to Bayesian theoryIntroduction to Bayesian theory
Introduction to Bayesian theory
Krishna Shriram.D
 
Genetic polymorphism in drug transport and drug targets.
Genetic polymorphism in drug transport and drug targets.Genetic polymorphism in drug transport and drug targets.
Genetic polymorphism in drug transport and drug targets.
pavithra vinayak
 
Therapeutic drug monitoring (TDM) of drugs used in seizure disorders
Therapeutic drug monitoring (TDM) of drugs used in seizure disordersTherapeutic drug monitoring (TDM) of drugs used in seizure disorders
Therapeutic drug monitoring (TDM) of drugs used in seizure disorders
Abel C. Mathew
 
DESIGN OF DOSAGE REGIMEN.pptx
DESIGN OF DOSAGE REGIMEN.pptxDESIGN OF DOSAGE REGIMEN.pptx
DESIGN OF DOSAGE REGIMEN.pptx
DrAniqaSundas
 
Effect of liver disease on pharmacokinetics
 Effect of liver disease on pharmacokinetics  Effect of liver disease on pharmacokinetics
Effect of liver disease on pharmacokinetics
pavithra vinayak
 
Protocol for tdm
Protocol for tdmProtocol for tdm
Protocol for tdm
SwarnaPriyaBasker
 
Population pharmacokinetics
Population pharmacokineticsPopulation pharmacokinetics
Population pharmacokinetics
Dr. Ramesh Bhandari
 
Individualization of drug dosage regimen
Individualization of drug dosage regimenIndividualization of drug dosage regimen
Individualization of drug dosage regimen
Dr. Ramesh Bhandari
 
Dose in uremia
Dose in uremiaDose in uremia
Dose in uremia
Gayathri Kannanunny
 
Dose adjustment in Renal Disorders
Dose adjustment in Renal DisordersDose adjustment in Renal Disorders
Dose adjustment in Renal Disorders
Dr. Ramesh Bhandari
 
Population pharmacokinetics
Population pharmacokineticsPopulation pharmacokinetics
Population pharmacokinetics
Krishna Shriram.D
 
Pharmacokinetic changes in renal impairment and dosage considerations
Pharmacokinetic changes in renal impairment and dosage considerationsPharmacokinetic changes in renal impairment and dosage considerations
Pharmacokinetic changes in renal impairment and dosage considerations
Dr Htet
 
NOMOGRAMS AND TABULATIONS IN DESIGNING DOSAGE REGIMEN.pptx
NOMOGRAMS AND TABULATIONS IN   DESIGNING DOSAGE REGIMEN.pptxNOMOGRAMS AND TABULATIONS IN   DESIGNING DOSAGE REGIMEN.pptx
NOMOGRAMS AND TABULATIONS IN DESIGNING DOSAGE REGIMEN.pptx
Firdous Ansari
 
Dosing in obese patient
Dosing in obese patientDosing in obese patient
Dosing in obese patient
Dr. Ramesh Bhandari
 
Pharmacoepidemiology and risk management
Pharmacoepidemiology and risk management Pharmacoepidemiology and risk management
Pharmacoepidemiology and risk management
Dr. Ashish singh parihar
 
Determination of dose and dosing interval
Determination of dose and dosing intervalDetermination of dose and dosing interval
Determination of dose and dosing interval
Dr. Ramesh Bhandari
 

What's hot (20)

Nomograms and tabulations in design of dosage regimens
Nomograms and tabulations in design of dosage regimens Nomograms and tabulations in design of dosage regimens
Nomograms and tabulations in design of dosage regimens
 
6. population pharmacokinetics
6. population pharmacokinetics6. population pharmacokinetics
6. population pharmacokinetics
 
Drug dosing in elderly, infant and obese patient slide share
Drug dosing in elderly, infant and obese patient slide shareDrug dosing in elderly, infant and obese patient slide share
Drug dosing in elderly, infant and obese patient slide share
 
Dose adjustment in Renal failure
Dose adjustment in Renal failure Dose adjustment in Renal failure
Dose adjustment in Renal failure
 
Introduction to Bayesian theory
Introduction to Bayesian theoryIntroduction to Bayesian theory
Introduction to Bayesian theory
 
Genetic polymorphism in drug transport and drug targets.
Genetic polymorphism in drug transport and drug targets.Genetic polymorphism in drug transport and drug targets.
Genetic polymorphism in drug transport and drug targets.
 
Therapeutic drug monitoring (TDM) of drugs used in seizure disorders
Therapeutic drug monitoring (TDM) of drugs used in seizure disordersTherapeutic drug monitoring (TDM) of drugs used in seizure disorders
Therapeutic drug monitoring (TDM) of drugs used in seizure disorders
 
DESIGN OF DOSAGE REGIMEN.pptx
DESIGN OF DOSAGE REGIMEN.pptxDESIGN OF DOSAGE REGIMEN.pptx
DESIGN OF DOSAGE REGIMEN.pptx
 
Effect of liver disease on pharmacokinetics
 Effect of liver disease on pharmacokinetics  Effect of liver disease on pharmacokinetics
Effect of liver disease on pharmacokinetics
 
Protocol for tdm
Protocol for tdmProtocol for tdm
Protocol for tdm
 
Population pharmacokinetics
Population pharmacokineticsPopulation pharmacokinetics
Population pharmacokinetics
 
Individualization of drug dosage regimen
Individualization of drug dosage regimenIndividualization of drug dosage regimen
Individualization of drug dosage regimen
 
Dose in uremia
Dose in uremiaDose in uremia
Dose in uremia
 
Dose adjustment in Renal Disorders
Dose adjustment in Renal DisordersDose adjustment in Renal Disorders
Dose adjustment in Renal Disorders
 
Population pharmacokinetics
Population pharmacokineticsPopulation pharmacokinetics
Population pharmacokinetics
 
Pharmacokinetic changes in renal impairment and dosage considerations
Pharmacokinetic changes in renal impairment and dosage considerationsPharmacokinetic changes in renal impairment and dosage considerations
Pharmacokinetic changes in renal impairment and dosage considerations
 
NOMOGRAMS AND TABULATIONS IN DESIGNING DOSAGE REGIMEN.pptx
NOMOGRAMS AND TABULATIONS IN   DESIGNING DOSAGE REGIMEN.pptxNOMOGRAMS AND TABULATIONS IN   DESIGNING DOSAGE REGIMEN.pptx
NOMOGRAMS AND TABULATIONS IN DESIGNING DOSAGE REGIMEN.pptx
 
Dosing in obese patient
Dosing in obese patientDosing in obese patient
Dosing in obese patient
 
Pharmacoepidemiology and risk management
Pharmacoepidemiology and risk management Pharmacoepidemiology and risk management
Pharmacoepidemiology and risk management
 
Determination of dose and dosing interval
Determination of dose and dosing intervalDetermination of dose and dosing interval
Determination of dose and dosing interval
 

Similar to Design of Dosage form

Therapeutic drug monitoring
Therapeutic  drug monitoringTherapeutic  drug monitoring
Therapeutic drug monitoring
Dr Sajeena Jose
 
Pharmacokinetics & BA - Part-2.pdf
Pharmacokinetics & BA - Part-2.pdfPharmacokinetics & BA - Part-2.pdf
Pharmacokinetics & BA - Part-2.pdf
SARADPAWAR1
 
Pharmacokinetics & BA - Part-2.pdf
Pharmacokinetics & BA - Part-2.pdfPharmacokinetics & BA - Part-2.pdf
Pharmacokinetics & BA - Part-2.pdf
SARADPAWAR1
 
therapeutic Drug Monitoring
therapeutic Drug Monitoring therapeutic Drug Monitoring
therapeutic Drug Monitoring
Areej Abu Hanieh
 
Bioavailability
BioavailabilityBioavailability
E4 GUIDELINE DOSE RESPONSE INFORMATION TO SUPPORT DRUG REGISTRATION
E4 GUIDELINE DOSE RESPONSE INFORMATION TO SUPPORT DRUG REGISTRATIONE4 GUIDELINE DOSE RESPONSE INFORMATION TO SUPPORT DRUG REGISTRATION
E4 GUIDELINE DOSE RESPONSE INFORMATION TO SUPPORT DRUG REGISTRATION
Charmi13
 
Therapeutic drug monitoring
Therapeutic  drug monitoringTherapeutic  drug monitoring
Therapeutic drug monitoring
Ramakanth Gadepalli
 
Designing of Dosage Regimen and Multiple Dosage Regimens
Designing of Dosage Regimen and Multiple Dosage RegimensDesigning of Dosage Regimen and Multiple Dosage Regimens
Designing of Dosage Regimen and Multiple Dosage Regimens
Shahriar Mohammad Shohan
 
Therapeutic Drug Monitoring
Therapeutic Drug MonitoringTherapeutic Drug Monitoring
Therapeutic Drug Monitoring
Dr. Ramesh Bhandari
 
General Introduction on therapeutic drug monitoring
General Introduction on therapeutic drug monitoringGeneral Introduction on therapeutic drug monitoring
General Introduction on therapeutic drug monitoring
Dr. Ramesh Bhandari
 
Therapeutic drug monitoring
Therapeutic drug monitoringTherapeutic drug monitoring
Therapeutic drug monitoring
Swarnakshi Upadhyay
 
THERAPEUTIC DRUG MONITORING- NPMCN 260722.pdf
THERAPEUTIC DRUG MONITORING- NPMCN 260722.pdfTHERAPEUTIC DRUG MONITORING- NPMCN 260722.pdf
THERAPEUTIC DRUG MONITORING- NPMCN 260722.pdf
Adamu Mohammad
 
THERAPEUTIC DRUG MONITORING- NPMCN 260722.pdf
THERAPEUTIC DRUG MONITORING- NPMCN 260722.pdfTHERAPEUTIC DRUG MONITORING- NPMCN 260722.pdf
THERAPEUTIC DRUG MONITORING- NPMCN 260722.pdf
Adamu Mohammad
 
THERAPEUTIC DRUG MONITORING- NPMCN 260722.pdf
THERAPEUTIC DRUG MONITORING- NPMCN 260722.pdfTHERAPEUTIC DRUG MONITORING- NPMCN 260722.pdf
THERAPEUTIC DRUG MONITORING- NPMCN 260722.pdf
Adamu Mohammad
 
Clinical pharmacokinetics
Clinical pharmacokineticsClinical pharmacokinetics
Clinical pharmacokinetics
Dr. Manu Kumar Shetty
 
Bioavailability and bioeqivalance testing
Bioavailability and bioeqivalance testing Bioavailability and bioeqivalance testing
Bioavailability and bioeqivalance testing
PromilaThakur4
 
Measurement of bioavailability and concept of equivalence
Measurement of bioavailability and concept of equivalenceMeasurement of bioavailability and concept of equivalence
Measurement of bioavailability and concept of equivalence
Ravish Yadav
 
E4 Presentation.pptx
E4 Presentation.pptxE4 Presentation.pptx
E4 Presentation.pptx
61BhaveshPatil
 
Pharmacology part 2
Pharmacology part 2Pharmacology part 2
Pharmacology part 2
NkosinathiManana2
 

Similar to Design of Dosage form (20)

Therapeutic drug monitoring
Therapeutic  drug monitoringTherapeutic  drug monitoring
Therapeutic drug monitoring
 
Pharmacokinetics & BA - Part-2.pdf
Pharmacokinetics & BA - Part-2.pdfPharmacokinetics & BA - Part-2.pdf
Pharmacokinetics & BA - Part-2.pdf
 
Pharmacokinetics & BA - Part-2.pdf
Pharmacokinetics & BA - Part-2.pdfPharmacokinetics & BA - Part-2.pdf
Pharmacokinetics & BA - Part-2.pdf
 
therapeutic Drug Monitoring
therapeutic Drug Monitoring therapeutic Drug Monitoring
therapeutic Drug Monitoring
 
Bioavailability
BioavailabilityBioavailability
Bioavailability
 
E4 GUIDELINE DOSE RESPONSE INFORMATION TO SUPPORT DRUG REGISTRATION
E4 GUIDELINE DOSE RESPONSE INFORMATION TO SUPPORT DRUG REGISTRATIONE4 GUIDELINE DOSE RESPONSE INFORMATION TO SUPPORT DRUG REGISTRATION
E4 GUIDELINE DOSE RESPONSE INFORMATION TO SUPPORT DRUG REGISTRATION
 
Ppt tdm new
Ppt tdm newPpt tdm new
Ppt tdm new
 
Therapeutic drug monitoring
Therapeutic  drug monitoringTherapeutic  drug monitoring
Therapeutic drug monitoring
 
Designing of Dosage Regimen and Multiple Dosage Regimens
Designing of Dosage Regimen and Multiple Dosage RegimensDesigning of Dosage Regimen and Multiple Dosage Regimens
Designing of Dosage Regimen and Multiple Dosage Regimens
 
Therapeutic Drug Monitoring
Therapeutic Drug MonitoringTherapeutic Drug Monitoring
Therapeutic Drug Monitoring
 
General Introduction on therapeutic drug monitoring
General Introduction on therapeutic drug monitoringGeneral Introduction on therapeutic drug monitoring
General Introduction on therapeutic drug monitoring
 
Therapeutic drug monitoring
Therapeutic drug monitoringTherapeutic drug monitoring
Therapeutic drug monitoring
 
THERAPEUTIC DRUG MONITORING- NPMCN 260722.pdf
THERAPEUTIC DRUG MONITORING- NPMCN 260722.pdfTHERAPEUTIC DRUG MONITORING- NPMCN 260722.pdf
THERAPEUTIC DRUG MONITORING- NPMCN 260722.pdf
 
THERAPEUTIC DRUG MONITORING- NPMCN 260722.pdf
THERAPEUTIC DRUG MONITORING- NPMCN 260722.pdfTHERAPEUTIC DRUG MONITORING- NPMCN 260722.pdf
THERAPEUTIC DRUG MONITORING- NPMCN 260722.pdf
 
THERAPEUTIC DRUG MONITORING- NPMCN 260722.pdf
THERAPEUTIC DRUG MONITORING- NPMCN 260722.pdfTHERAPEUTIC DRUG MONITORING- NPMCN 260722.pdf
THERAPEUTIC DRUG MONITORING- NPMCN 260722.pdf
 
Clinical pharmacokinetics
Clinical pharmacokineticsClinical pharmacokinetics
Clinical pharmacokinetics
 
Bioavailability and bioeqivalance testing
Bioavailability and bioeqivalance testing Bioavailability and bioeqivalance testing
Bioavailability and bioeqivalance testing
 
Measurement of bioavailability and concept of equivalence
Measurement of bioavailability and concept of equivalenceMeasurement of bioavailability and concept of equivalence
Measurement of bioavailability and concept of equivalence
 
E4 Presentation.pptx
E4 Presentation.pptxE4 Presentation.pptx
E4 Presentation.pptx
 
Pharmacology part 2
Pharmacology part 2Pharmacology part 2
Pharmacology part 2
 

More from Dr. Ramesh Bhandari

Designing Protocol.pdf
Designing Protocol.pdfDesigning Protocol.pdf
Designing Protocol.pdf
Dr. Ramesh Bhandari
 
Communicable diseases
Communicable diseasesCommunicable diseases
Communicable diseases
Dr. Ramesh Bhandari
 
Causality Assessment ADR.pdf
Causality Assessment ADR.pdfCausality Assessment ADR.pdf
Causality Assessment ADR.pdf
Dr. Ramesh Bhandari
 
Microbiological culture sensitivity tests
Microbiological culture sensitivity testsMicrobiological culture sensitivity tests
Microbiological culture sensitivity tests
Dr. Ramesh Bhandari
 
Respiratory and Intestinal infections
Respiratory and Intestinal infectionsRespiratory and Intestinal infections
Respiratory and Intestinal infections
Dr. Ramesh Bhandari
 
Epidemiology
EpidemiologyEpidemiology
Epidemiology
Dr. Ramesh Bhandari
 
Microbiology
MicrobiologyMicrobiology
Microbiology
Dr. Ramesh Bhandari
 
Nutrition and Food
Nutrition and FoodNutrition and Food
Nutrition and Food
Dr. Ramesh Bhandari
 
Effect of environment on health
Effect of environment on healthEffect of environment on health
Effect of environment on health
Dr. Ramesh Bhandari
 
Vaccine and immunity
Vaccine and immunityVaccine and immunity
Vaccine and immunity
Dr. Ramesh Bhandari
 
Psychosocial pharmacy
Psychosocial pharmacyPsychosocial pharmacy
Psychosocial pharmacy
Dr. Ramesh Bhandari
 
Nutrition
NutritionNutrition
Mother and child health
Mother and child healthMother and child health
Mother and child health
Dr. Ramesh Bhandari
 
Demography, demographic cycle and family planning methods
Demography, demographic cycle and family planning methodsDemography, demographic cycle and family planning methods
Demography, demographic cycle and family planning methods
Dr. Ramesh Bhandari
 
National health policy, MDGs, SDPs, and FIP Development Goals
National health policy, MDGs, SDPs, and FIP Development GoalsNational health policy, MDGs, SDPs, and FIP Development Goals
National health policy, MDGs, SDPs, and FIP Development Goals
Dr. Ramesh Bhandari
 
Concept, Dimension, Determinants, and Indicators of health
Concept, Dimension, Determinants, and Indicators of healthConcept, Dimension, Determinants, and Indicators of health
Concept, Dimension, Determinants, and Indicators of health
Dr. Ramesh Bhandari
 
Social pharmacy, National Health Mission
Social pharmacy, National Health MissionSocial pharmacy, National Health Mission
Social pharmacy, National Health Mission
Dr. Ramesh Bhandari
 
Safety Data Generation
Safety Data GenerationSafety Data Generation
Safety Data Generation
Dr. Ramesh Bhandari
 
ICH Guidelines for Pharmacovigilance
ICH Guidelines for PharmacovigilanceICH Guidelines for Pharmacovigilance
ICH Guidelines for Pharmacovigilance
Dr. Ramesh Bhandari
 
Pharmacovigilance methods
Pharmacovigilance methodsPharmacovigilance methods
Pharmacovigilance methods
Dr. Ramesh Bhandari
 

More from Dr. Ramesh Bhandari (20)

Designing Protocol.pdf
Designing Protocol.pdfDesigning Protocol.pdf
Designing Protocol.pdf
 
Communicable diseases
Communicable diseasesCommunicable diseases
Communicable diseases
 
Causality Assessment ADR.pdf
Causality Assessment ADR.pdfCausality Assessment ADR.pdf
Causality Assessment ADR.pdf
 
Microbiological culture sensitivity tests
Microbiological culture sensitivity testsMicrobiological culture sensitivity tests
Microbiological culture sensitivity tests
 
Respiratory and Intestinal infections
Respiratory and Intestinal infectionsRespiratory and Intestinal infections
Respiratory and Intestinal infections
 
Epidemiology
EpidemiologyEpidemiology
Epidemiology
 
Microbiology
MicrobiologyMicrobiology
Microbiology
 
Nutrition and Food
Nutrition and FoodNutrition and Food
Nutrition and Food
 
Effect of environment on health
Effect of environment on healthEffect of environment on health
Effect of environment on health
 
Vaccine and immunity
Vaccine and immunityVaccine and immunity
Vaccine and immunity
 
Psychosocial pharmacy
Psychosocial pharmacyPsychosocial pharmacy
Psychosocial pharmacy
 
Nutrition
NutritionNutrition
Nutrition
 
Mother and child health
Mother and child healthMother and child health
Mother and child health
 
Demography, demographic cycle and family planning methods
Demography, demographic cycle and family planning methodsDemography, demographic cycle and family planning methods
Demography, demographic cycle and family planning methods
 
National health policy, MDGs, SDPs, and FIP Development Goals
National health policy, MDGs, SDPs, and FIP Development GoalsNational health policy, MDGs, SDPs, and FIP Development Goals
National health policy, MDGs, SDPs, and FIP Development Goals
 
Concept, Dimension, Determinants, and Indicators of health
Concept, Dimension, Determinants, and Indicators of healthConcept, Dimension, Determinants, and Indicators of health
Concept, Dimension, Determinants, and Indicators of health
 
Social pharmacy, National Health Mission
Social pharmacy, National Health MissionSocial pharmacy, National Health Mission
Social pharmacy, National Health Mission
 
Safety Data Generation
Safety Data GenerationSafety Data Generation
Safety Data Generation
 
ICH Guidelines for Pharmacovigilance
ICH Guidelines for PharmacovigilanceICH Guidelines for Pharmacovigilance
ICH Guidelines for Pharmacovigilance
 
Pharmacovigilance methods
Pharmacovigilance methodsPharmacovigilance methods
Pharmacovigilance methods
 

Recently uploaded

Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.GawadHemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
NephroTube - Dr.Gawad
 
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stock
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in StockFactory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stock
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stock
rebeccabio
 
Couples presenting to the infertility clinic- Do they really have infertility...
Couples presenting to the infertility clinic- Do they really have infertility...Couples presenting to the infertility clinic- Do they really have infertility...
Couples presenting to the infertility clinic- Do they really have infertility...
Sujoy Dasgupta
 
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
GL Anaacs
 
Charaka Samhita Sutra Sthana 9 Chapter khuddakachatuspadadhyaya
Charaka Samhita Sutra Sthana 9 Chapter khuddakachatuspadadhyayaCharaka Samhita Sutra Sthana 9 Chapter khuddakachatuspadadhyaya
Charaka Samhita Sutra Sthana 9 Chapter khuddakachatuspadadhyaya
Dr KHALID B.M
 
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists  Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Saeid Safari
 
Ocular injury ppt Upendra pal optometrist upums saifai etawah
Ocular injury  ppt  Upendra pal  optometrist upums saifai etawahOcular injury  ppt  Upendra pal  optometrist upums saifai etawah
Ocular injury ppt Upendra pal optometrist upums saifai etawah
pal078100
 
How to Give Better Lectures: Some Tips for Doctors
How to Give Better Lectures: Some Tips for DoctorsHow to Give Better Lectures: Some Tips for Doctors
How to Give Better Lectures: Some Tips for Doctors
LanceCatedral
 
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...
kevinkariuki227
 
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...
i3 Health
 
Are There Any Natural Remedies To Treat Syphilis.pdf
Are There Any Natural Remedies To Treat Syphilis.pdfAre There Any Natural Remedies To Treat Syphilis.pdf
Are There Any Natural Remedies To Treat Syphilis.pdf
Little Cross Family Clinic
 
The POPPY STUDY (Preconception to post-partum cardiovascular function in prim...
The POPPY STUDY (Preconception to post-partum cardiovascular function in prim...The POPPY STUDY (Preconception to post-partum cardiovascular function in prim...
The POPPY STUDY (Preconception to post-partum cardiovascular function in prim...
Catherine Liao
 
THOA 2.ppt Human Organ Transplantation Act
THOA 2.ppt Human Organ Transplantation ActTHOA 2.ppt Human Organ Transplantation Act
THOA 2.ppt Human Organ Transplantation Act
DrSathishMS1
 
Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...
Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...
Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...
Savita Shen $i11
 
Antiulcer drugs Advance Pharmacology .pptx
Antiulcer drugs Advance Pharmacology .pptxAntiulcer drugs Advance Pharmacology .pptx
Antiulcer drugs Advance Pharmacology .pptx
Rohit chaurpagar
 
KDIGO 2024 guidelines for diabetologists
KDIGO 2024 guidelines for diabetologistsKDIGO 2024 guidelines for diabetologists
KDIGO 2024 guidelines for diabetologists
د.محمود نجيب
 
Charaka Samhita Sutra sthana Chapter 15 Upakalpaniyaadhyaya
Charaka Samhita Sutra sthana Chapter 15 UpakalpaniyaadhyayaCharaka Samhita Sutra sthana Chapter 15 Upakalpaniyaadhyaya
Charaka Samhita Sutra sthana Chapter 15 Upakalpaniyaadhyaya
Dr KHALID B.M
 
The Normal Electrocardiogram - Part I of II
The Normal Electrocardiogram - Part I of IIThe Normal Electrocardiogram - Part I of II
The Normal Electrocardiogram - Part I of II
MedicoseAcademics
 
BRACHYTHERAPY OVERVIEW AND APPLICATORS
BRACHYTHERAPY OVERVIEW  AND  APPLICATORSBRACHYTHERAPY OVERVIEW  AND  APPLICATORS
BRACHYTHERAPY OVERVIEW AND APPLICATORS
Krishan Murari
 
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
bkling
 

Recently uploaded (20)

Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.GawadHemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
 
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stock
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in StockFactory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stock
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stock
 
Couples presenting to the infertility clinic- Do they really have infertility...
Couples presenting to the infertility clinic- Do they really have infertility...Couples presenting to the infertility clinic- Do they really have infertility...
Couples presenting to the infertility clinic- Do they really have infertility...
 
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
 
Charaka Samhita Sutra Sthana 9 Chapter khuddakachatuspadadhyaya
Charaka Samhita Sutra Sthana 9 Chapter khuddakachatuspadadhyayaCharaka Samhita Sutra Sthana 9 Chapter khuddakachatuspadadhyaya
Charaka Samhita Sutra Sthana 9 Chapter khuddakachatuspadadhyaya
 
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists  Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
 
Ocular injury ppt Upendra pal optometrist upums saifai etawah
Ocular injury  ppt  Upendra pal  optometrist upums saifai etawahOcular injury  ppt  Upendra pal  optometrist upums saifai etawah
Ocular injury ppt Upendra pal optometrist upums saifai etawah
 
How to Give Better Lectures: Some Tips for Doctors
How to Give Better Lectures: Some Tips for DoctorsHow to Give Better Lectures: Some Tips for Doctors
How to Give Better Lectures: Some Tips for Doctors
 
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...
 
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...
 
Are There Any Natural Remedies To Treat Syphilis.pdf
Are There Any Natural Remedies To Treat Syphilis.pdfAre There Any Natural Remedies To Treat Syphilis.pdf
Are There Any Natural Remedies To Treat Syphilis.pdf
 
The POPPY STUDY (Preconception to post-partum cardiovascular function in prim...
The POPPY STUDY (Preconception to post-partum cardiovascular function in prim...The POPPY STUDY (Preconception to post-partum cardiovascular function in prim...
The POPPY STUDY (Preconception to post-partum cardiovascular function in prim...
 
THOA 2.ppt Human Organ Transplantation Act
THOA 2.ppt Human Organ Transplantation ActTHOA 2.ppt Human Organ Transplantation Act
THOA 2.ppt Human Organ Transplantation Act
 
Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...
Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...
Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...
 
Antiulcer drugs Advance Pharmacology .pptx
Antiulcer drugs Advance Pharmacology .pptxAntiulcer drugs Advance Pharmacology .pptx
Antiulcer drugs Advance Pharmacology .pptx
 
KDIGO 2024 guidelines for diabetologists
KDIGO 2024 guidelines for diabetologistsKDIGO 2024 guidelines for diabetologists
KDIGO 2024 guidelines for diabetologists
 
Charaka Samhita Sutra sthana Chapter 15 Upakalpaniyaadhyaya
Charaka Samhita Sutra sthana Chapter 15 UpakalpaniyaadhyayaCharaka Samhita Sutra sthana Chapter 15 Upakalpaniyaadhyaya
Charaka Samhita Sutra sthana Chapter 15 Upakalpaniyaadhyaya
 
The Normal Electrocardiogram - Part I of II
The Normal Electrocardiogram - Part I of IIThe Normal Electrocardiogram - Part I of II
The Normal Electrocardiogram - Part I of II
 
BRACHYTHERAPY OVERVIEW AND APPLICATORS
BRACHYTHERAPY OVERVIEW  AND  APPLICATORSBRACHYTHERAPY OVERVIEW  AND  APPLICATORS
BRACHYTHERAPY OVERVIEW AND APPLICATORS
 
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
 

Design of Dosage form

  • 1. Design of Dosage Regimen Dr. Ramesh Bhandari Assistant Professor Department of Pharmacy Practice KLE College of Pharmacy, Belagavi
  • 2. Difference between dosage form and dosage regimen Dosage form: the way in which a therapeutic agent in taken or administered (tablet, capsule, spray). Dosage regimen: the schedule of doses per unit of time ( no. of doses and interval).
  • 3. Introduction • Dosage regimen design is the selection of drug dosage, route, and frequency of administration in an informed manner to achieve therapeutic objectives. • At the same time, the variability among patients in pharmacodynamic response demands individualized dosing to assure maximum efficacy. • Planning of drug therapy is necessary because the administration of drugs usually involves risk of untoward effects.
  • 4. Several Methods Used to Design a Dosage Regimen 1) Individualized Dosage Regimen 2) Dosage Regimens based on Population averages 3) Dosage Regimens based on Partial Pharmacokinetic parameters 4) Empirical Dosage Regimen 5) Nomogram and Tabulation in Dosage Regimen
  • 5. 1) Individualized Dosage Regimens Most accurate approach  Dose calculated based on the pharmacokinetics of the drug in the individual patient derived from measurement of serum / plasma drug levels Not feasible for calculation of the initial dose, however, once the patient has been medicated, readjustment of the dose may be done. Most dosing program record the patient’s age and weight and calculate the individual dose based on creatinine clearance and lean body weight.
  • 6. 2) Dosage regimen based on population Averages The method most often used to calculate a dosage regimen is based on average pharmacokinetic parameters obtained from clinical studies published in the drug literature. There are 2 approaches followed: a) Fixed model b)Adaptive model
  • 7. a) Fixed Model • Assumes that population average pharmacokinetic parameters may be used directly to calculate a dosage regimen for the patient, without any alteration. • The practitioner may use the usual dosage suggested by the literature and then make a small adjustment of the dosage based on the patient’s weight and / or age • Usually, pharmacokinetic parameters such as Ka, F, Vd, k are assumed remain constant and most often drug is assumed to follow one compartment open model • When a multiple dose regimen is designed, multiple dosage equations based on the principle of superposition are used to evaluate the dose.
  • 8. b) Adaptive Model • Attempts to adapt or modify dosage regimen according to the need of the patient. • Uses patient variable such as weight, age, sex, body surface area, and known patient’s pathophysiology such as, renal disease, as well as known population average pharmacokinetic parameters of the drug. • This model generally assumes that pharmacokinetic parameters such as drug clearance do not change from one dose to the next. • However, some adaptive models allow for continuously adaptive change with time in order to simulate more closely the changing process of drug disposition in the patient, especially during a disease state.
  • 9. 3) Dosage regimen based on partial PK Parameter • For many drugs, the entire pharmacokinetic profile for the drug is unknown or unavailable. • Therefore, the pharmacokineticist needs to make some assumptions in order to calculate the dosage regimen. • These assumptions will depend on the safety, efficacy, and therapeutic range of the drug. • The use of population pharmacokinetics uses average patient population characteristics and only a few serum / plasma concentration from the patient • Population pharmacokinetic approaches to therapeutic drug monitoring have increased with the increased availability of computerized data bases and development of statistical tools for the analysis of observational data.
  • 10. 4) Empirical Dosage Regimen • In many cases, physician selects a dosage regimen of the patient without using any pharmacokinetic variables. • The physician makes the decision based on empirical clinical data, personal experience and clinical observations.
  • 11. 5) Nomograms andTabulation in Designing Dosage Regimen • For ease of calculation of dosage regimens, many clinicians rely on nomograms to calculate the proper dosage regimen for their patients. • The use of nomogram may give a quick dosage regimen adjustment for patients with characteristics requiring adjustments such as age, body weight, and physiologic state. • In general, nomogram of a drug is based on population pharmacokinetic data collected and analyzed using a specific pharmacokinetic model.
  • 12. Nomograms andTabulation in Designing Dosage Regimen • A nomogram typically has three scales: two scales represent known values and one scale is the scale where the result is read off. • The known scales are placed on the outside; i.e. the result scale is in the center. • Each known value of the calculation is marked on the outer scales and a line is drawn between each mark. • Where the line and the inside scale intersects is the result. • Examples include: height – BMI – weight, total clearance – maintenance dose – lean body weight, etc.
  • 13. Nomograms andTabulation in Designing Dosage Regimen • In order to keep the dosage regimen calculation simple, complicated equations are often solved and their results displayed diagrammatically on special scaled axes to produce a simple dose recommendation based on patient information. • Some nomograms make use of certain physiologic parameters, such as serum creatinine concentration, to help modify the dosage regimen according to renal function. • For many marketed drugs, the manufacturer provides tabulated general guidelines for use in establishing a dosage regimen for patients, including loading and maintenance doses.
  • 14. Examples of drugs for which nomograms are being used for designing dosage regimen: • Theophylline • Aminoglycosides:Tobramycin sulfate • Warfarin • Digoxin etc.
  • 16. Importance of IV to PO Conversion oral formulations are easier to administer, safe, and achieve desired therapeutic concentrations, thus making the PO route an ideal choice. More Comfortable Cost Effective: reduces hidden expenses IV therapy restrict the movement and make more prone to IV related adverse effects. Furthermore, IV route make portal for bacteria and fungal infections.
  • 17. Types of IV to PO therapy Conversion 1) Sequential Therapy 2) Switch Therapy 3) Step-down Therapy
  • 18. 1) SequentialTherapy It refers to the act of replacing a parenteral version of a medication with its oral counterpart. There are many classes of medications that have oral dosage forms that are therapeutically equivalent to the parenteral form of the same medication. E.g. conversion of famotidine 20 mg IV to famotidine 20 mg PO.
  • 19. 2) SwitchTherapy Used to describe a conversion from an IV medication to the PO equivalent that may be within the same class and have the same level of potency, but is a different compound. An example is the conversion of IV pantoprazole to rapidly dissolving lansoprazole tablets omeprazole capsules.
  • 20. 3) Step-downTherapy It refers to converting from an injectable medication to an oral agent in another class or to a different medication within the same class where the frequency, dose, and the spectrum of activity (in the case of antibiotics) may not be exactly the same. Converting from ampicillin 3 g IV q 6 hr to amoxicillin 875 mg PO q 12 hr is an example of step-down therapy.
  • 21. SELECTION OF PATIENT FOR IVTO POTHERAPY CONVERSION I. Intact and functioning of GI tract II. Improving patient condition III.Doesn't meet exclusion criteria IV.Others
  • 22. Pharmacokinetic Consideration • For oral medications, bioavailability may be less due to the variability in the rate and extent of dissolution of the oral form and the total amount that is absorbed into the systemic circulation.
  • 23. • When intravenous infusion is stopped, the serum drug concentration decreases according to first-order elimination kinetics. • For most oral drug products, the time to reach steady state depends on the first-order elimination rate constant for the drug. • Therefore, if the patient starts the dosage regimen with the oral drug product at the same time as the intravenous infusion is stopped, then the exponential decline of serum levels from the intravenous infusion should be matched by the exponential increase in serum drug levels from the oral drug product.
  • 24. • Following two methods may be used to calculate an appropriate oral dosage regimen for a patient whose condition has been stabilized by an intravenous drug infusion. • Both methods assume that the patient’s plasma drug concentration is at steady state.
  • 25. METHOD I C∞ av = SFD0 / k Vd τ D0 / τ = C∞ av . k Vd / SF Where, S is the salt form of the drug and D0 / τ is the dosing rate
  • 26. METHOD II • This method assumes that the rate of intravenous infusion (mg/hr) is the same desired rate of oral dosage.
  • 27. EXAMPLE • An adult male asthmatic patient (age 55, 78 kg) has been maintained on an IV infusion of aminophylline at a rate of 34 mg/hr. The steady state theophylline drug concentration was 12 µg/mL and total body clearance was calculated as 3.0 L/hr. Calculate an appropriate oral dosage regimen of theophylline for this patient. (Aminophylline is a soluble salt of theophylline and contains 85% theophylline (S = 0.85). Theophylline is 100% bioavailable (F = 1) after an oral dose.)
  • 28. Solution by Method - I We know, D0 / τ = C∞ av . k Vd / SF But, total body clearance (ClT) = kVd Therefore, D0 / τ = C∞ av ClT/ SF • The dose rate (34 mg/hr) was calculated on the basis of aminophylline dosing. • The patient however will be given theophylline orally, to convert to oral theophylline S and F should be considered Oral theophylline dose rate = SFD0 / τ = (0.85) (1) (34) / 1 = 28.9 mg / hr • Therefore the total daily dose is 28.9 mg/hr x 24 hr or 693.6 mg/day • Possible theophylline schedules might be 700 mg/day. • The dose of 350 mg every 12 hours could be given in sustained-release form to avoid any excessive high drug concentration in the body.
  • 29. Solution by Method - II Rate of IV infusion is 34 mg/hr and so the daily dose is 34 mg/hr x 24 = 816 mg/day. The equivalent dose in terms of theophylline is 816 x 0.85 = 693.6 mg. Thus the patient should receive approximately 700 mg of theophylline per day or 350 mg every 12 hours.